Abstract:Abstract Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is approved in the USA, EU, UK and other countries for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. Deucravacitinib was efficacious and well tolerated in the global, 52-week, phase III POETYK PSO-1 (NCT03624127) and POETYK PSO-2 (NCT03611751) trials in moderate-to-severe plaque psoriasis. It also maintained efficacy through 3 years with no new safety signals in the POETYK long-term extension (LTE) (NCT04036435) trial. Older patients (≥ 65 years) typically have more comorbidities and may have increased risk of adverse events (AEs). Many clinical studies of novel psoriasis agents excluded older patients, limiting the generalizability of reported safety profiles. This post hoc analysis evaluated the safety profile of deucravacitinib in older (≥ 65 years) and younger (< 65 years) patients through 3 years in the POETYK trials. POETYK PSO-1 and PSO-2 randomized eligible patients 1 : 2 : 1 to oral placebo, deucravacitinib 6 mg once daily, or apremilast 30 mg twice daily. At week 52, patients could enrol in the LTE and receive open-label deucravacitinib. Safety was evaluated through 3 years in patients originally randomized to placebo or deucravacitinib (data cutoff 15 June 2022) using two key AE outcomes, serious AEs (SAEs) and discontinuation due to AEs (DcAEs), based on baseline age (≥ 65 years and < 65 years). Outcomes were expressed as exposure-adjusted incidence rates per 100 person-years (EAIR/100 PY) in patients who received at least one dose of deucravacitinib. There were fewer patients aged ≥ 65 years than < 65 years in the placebo (n = 79 and n = 587, respectively) and deucravacitinib (n = 133 and n = 1231) treatment groups. EAIRs/100 PY for SAEs over weeks 0–52 were higher in patients aged ≥ 65 years compared with patients aged < 65 years receiving placebo (10.2 and 5.0, respectively) or deucravacitinib (14.6 and 4.8). For DcAEs, EAIRs/100 PY were 10.1 and 9.2, respectively, with placebo, and 11.9 and 3.6 with deucravacitinib. Incidence rates in each age group remained consistent or decreased through 3 years in the LTE trial with continued deucravacitinib treatment (SAEs: ≥ 65 years, 10.3; < 65 years, 5.0; DcAEs: ≥ 65 years, 5.1; < 65 years, 2.1). Deucravacitinib maintained a consistent safety profile through 3 years of exposure for both older and younger patients. As expected, AEs were higher in older vs. younger patients in both treatment groups. Rates of SAEs and DcAEs with deucravacitinib were comparable with placebo in both age groups in year 1 and were similar or trended down with long-term deucravacitinib treatment through 3 years. Conflicts of interest: N.K. has received speaker fees from Janssen and UCB, and honoraria from AbbVie, Janssen, Eli Lilly, Novartis and UCB. A.P. has received investigator, speaker or advisor fees, educational support and research grants from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galderma, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi and UCB. K.H. is a consultant for Bristol Myers Squibb via Syneos Health. R.M.K., S.B., A.R. and J.M. are employees and shareholders of Bristol Myers Squibb. R.B.W. has received research grants from AbbVie, Almirall, Amgen, Celgene, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer and UCB; and consulting fees from AbbVie, Almirall, Amgen, Astellas, Boehringer Ingelheim, Celgene, Dice Therapeutics, Eli Lilly, GSK, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi, UCB and UNION Therapeutics.

Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated With Disease Activity, Pharmacodynamics, and Clinical Responses

Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial

Improvements in patient‐reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: results from a randomized phase 2 trial

Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase 3 poetyk trials

Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials

Deucravacitinib in moderate‐to‐severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO‐1 and PSO‐2)

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial

Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials

Deucravacitinib for the Treatment of Psoriatic Disease

Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Patients from China Mainland, Taiwan, and South Korea with Moderate to Severe Plaque Psoriasis: a Phase 3 Randomized Clinical Trial

Efficacy and safety of the selective TYK2 inhibitor, deucravacitinib, in Japanese patients with moderate to severe plaque psoriasis: Subgroup analysis of a randomized, double-blind, placebo-controlled, global phase 3 trial

Deucravacitinib in the treatment of psoriasis

Deucravacitinib, a selective tyrosine kinase 2 inhibitor, for the treatment of moderate-to-severe plaque psoriasis

Deucravacitinib: A Novel TYK2 Inhibitor for the Treatment of Moderate-to-Severe Psoriasis

Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis

Selective TYK2 Inhibition in the Treatment of Moderate to Severe Chronic Plaque Psoriasis

Deucravacitinib for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: Efficacy and safety results from an open‐label, phase 3 trial

P096 Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in moderate-to-severe plaque psoriasis: safety profile in older (≥ 65 years) and younger (< 65 years) patients in the phase III POETYK PSO-1, PSO-2 and long-term extension trials